Project Grant K22CA292567
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $193K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $3,182,665 to The Washington University to investigate how natural killer (NK) cells can subvert the effectiveness of immune checkpoint therapy for cancer treatment. The key objectives are to: 1) elucidate the mechanisms by which NK cells constrain the efficacy of immune checkpoint therapy, 2) evaluate the contribution of the NKG2D receptor in this process, and 3) translate the findings...
- This federal Project Grant award of $222,998.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at the University of California, San Diego (UCSD) to develop a novel virus-like particle (VLP) vector for engineering endogenous immune cells to express chimeric antigen receptors (CARs). The goal is to enable these engineered immune cells, including T cells, NK cells, and macrophages, to mediate potent killing of ovarian cancer cells. This...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) in the amount of $109,076 is funding research at Case Western Reserve University (CWRU) to investigate the role of B-cell Activating Factor (BAFF) in the pathophysiology of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), two potentially life-threatening adverse events associated with chimeric antigen receptor (CAR)-T cell therapy. The...
- This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $150,878 to the Regents of the University of Minnesota (doing business as the Office of Sponsored Projects Administration) to support research on tissue-resident adaptive CD56bright natural killer (NK) cell responses in cancer. The key objectives are to advance the understanding of the functions of CD56bright "bright-tank" NK cell populations in tumors and identify mechanisms...
- The National Institutes of Health, National Cancer Institute awarded a $140,433 Project Grant to The Leland Stanford Junior University under the Cancer Research Manpower (CFDA 93.398) program. The award will be used to generate CD19.28Z chimeric antigen receptor (CAR) T cells in vivo using a Programmable Antibody-mediated Cellular Knock-in of T cells (PACK-IT) system. The goals are to optimize the PACK-IT system, compare the resulting PACK-IT CAR-T cells to conventionally manufactured CAR-T...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $827,942.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate a novel inhibitory receptor that regulates the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The key objectives are to: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), awarded a $399,444 Project Grant to Cancure LLC (Canzx Biotherapeutics) on August 1, 2025. The funding will support a feasibility study of a novel agent that aims to stimulate NK (natural killer) and CD8 T cells for potential use in treating solid tumors. The study seeks to address challenges with persistence and sustained function of these cell-based therapies in the solid...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- The National Cancer Institute awarded a $176,040 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027 under the Cancer Research Manpower (CFDA 93.398) federal grant program. The goal of this project is to develop new strategies to engineer CAR-T cells that can overcome the cancer cell glycocalyx barrier in solid tumors. This will involve: (1) engineering CAR-T cells to strengthen the immune synapse by enhancing binding to the...